Mualliflar

  • Гадаев А.Г., Агзамходжаева С.С., Нуритдинов Н.А., Пирматова Н.В.

##semicolon##

alkogolsiz yog’li jigar kasalligi, jigar fibrozi, yurak- qon tomir kasalliklari, erkaklar, xavf.

##submission.citations##

1. Андреев ДН, Маев ИВ, Дичева ДТ, Кузнецова ЕИ. Con- silium Medicum.2017;1:8-13.

2. Eslam M, Newsome PN, Sarin SK et al. A new definition for metabolic dysfunction-associated fatty liver disease: An in- ternational expert consensus statement. Lancet Gastroenterol Hepatol.2020;5(5):484-98.

3. Jichitu A, Bungau S, Stanescu AMA et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Patho- physiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel).2021;11(4):689.

4. Koutoukidis DA, Koshiaris C, Henry JA et al. The effect of lifestyle interventions on non-alcoholic fatty liver disease: A me- ta-analysis. Lancet Gastroenterol Hepatol.2021;6(3):231-244.

5. Rinella ME, Lazarus JV, Ratziu V et al. A multi-so- ciety consensus on NAFLD nomenclature. Hepatolo- gy.2023;77(3):1021-1032.

6. Stanton MC, Chen S-C, Jackson JV et al. Inflammatory signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice. J In- flamm.2011;8:8.

7. Tapper EB, Loomba R. Noninvasive imaging biomarker assessment of liver fibrosis. Gastroenterolo- gy.2020;158(5):1469-1483.

8. Younossi ZM, Golabi P, de Avila L et al. The global ep- idemiology of NAFLD and NASH in patients with type 2 di- abetes: A systematic review and meta-analysis. Hepatolo- gy.2022;76(3):1233-1246.